Probably a very informative post but I’ll wait for the readers digest version or the movie.
What we do know is the vaxx F’d up a lot of people and killed others.
In before the jab pushers
Should we take this report seriously?
Why post something this tedius. Are there cliff notes.
Bump for later.
Looks like enough reading on this post to keep one up half the night & learn...what?
I took a stab at making sense of the result reported early in the document. I’m not familiar with the terminology used to describe the study’s methodology. Here it goes...
- - - - -
OE ratio - Observed (post vax) to Expected (pre vax) ratio. Values greater than 1.0 indicate an increase in the respective condition
- study compared observed with expected rates of 13 selected AESI across neurological, haematological, and cardiac outcomes.
- Risks were assessed using observed versus expected (OE) ratios with 95 % confidence intervals.
- Prioritised potential safety signals were those with lower bound of the 95 % confidence interval (LBCI) greater than 1.5.
Assuming 95% confidence interval refers to the likelihood of reliable data sampling. The LBCI seems to point to the the “least reliable” sampling of the 95% CI. The Prioritized signals had an OE of at least 1.5 (my understanding)
Expected rates were obtained by participating sites using pre-COVID-19 vaccination healthcare data stratified by age and sex. Observed rates were reported from the same healthcare datasets since COVID-19 vaccination program rollout. AESI occurring up to 42 days following vaccination with mRNA (BNT162b2 and mRNA-1273) and adenovirus-vector (ChAdOx1) vaccines were included in the primary analysis. Risks were assessed using observed versus expected (OE) ratios with 95 % confidence intervals. Prioritised potential safety signals were those with lower bound of the 95 % confidence interval (LBCI) greater than 1.5.
Results Participants included 99,068,901 vaccinated individuals. In total, the qty administered in the study period:
- 183,559,462 doses of BNT162b2
- 36,178,442 doses of mRNA-1273
- 23,093,399 doses of ChAdOx1
Risk periods following homologous vaccination schedules contributed 23,168,335 person-years of follow-up. OE ratios with LBCI > 1.5 were observed.
Following the first dose of ChAdOx1 vaccine:
- Guillain-Barré syndrome (2.49, 95 % CI: 2.15, 2.87)
- cerebral venous sinus thrombosis (3.23, 95 % CI: 2.51, 4.09)
Following the first dose of mRNA-1273 vaccine:
- Acute disseminated encephalomyelitis showed an OE ratio of 3.78 (95 % CI: 1.52, 7.78)
The OE ratios for myocarditis and pericarditis following BNT162b2, mRNA-1273, and ChAdOx1 were significantly increased with LBCIs > 1.5.
Te above report is the results from all the people managing the adverse events of special interest (AESI) following COVID-19 vaccination from 10 sites across eight countries. Their conclusion:
This multi-country analysis confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis. Other potential safety signals that require further investigation were identified. The results suggest that many excess events may be coincidental and do not establish association nor indicate causality. The benefits of vaccination substantially outweigh the risks.